Impact of microRNA-21 on the development of clinical variations and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy

Read full text Summarise with VIRAT
Authors: Tashina E.I., E. A. Privalova, V. Yu. Kaplunova, Y. U. N. Belenkov
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aim. To evaluate the impact of microRNA-21 expression levels on the development of clinical variants and risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Material and methods. The study included 84 participants as follows: 42 patients (22 men and 20 women) with a confirmed diagnosis of HCM, and 42 patients without HCM, matched for sex and age (the control group). The mean age of the participants was 57,2±14,2 years. All participants underwent a comprehensive examination, including electrocardiography, echocardiography assessing hypertrophy and diastolic function parameters, Holter monitoring, and laboratory tests (including N-terminal probrain natriuretic peptide). For molecular biology analysis, circulating microRNA-21 levels in plasma were measured in all participants using real-time polymerase chain reaction. Results. MicroRNA-21 levels were significantly elevated in all patients with HCM compared to the control group (p

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies MicroRNA in disease regulation Cardiovascular Effects of Exercise

Publication details

Journal / source
Russian Journal of Cardiology
Volume
31
Issue
2
Pages
6632–6632
Publication date
29 March 2026
Language
EN